# Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis

> **NCT05920018** · NA · RECRUITING · sponsor: **Universität Münster** · enrollment: 100 (estimated)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DIETARY_SUPPLEMENT:** Vivomixx®
- **DIETARY_SUPPLEMENT:** Conjugated linoleic acid (CLA/Tonalin® FFA 80)
- **OTHER:** Maltose placebo
- **OTHER:** Sunflower oil placebo

## Key facts

- **NCT ID:** NCT05920018
- **Lead sponsor:** Universität Münster
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-02
- **Primary completion:** 2025-02
- **Final completion:** 2025-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05920018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05920018, "Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05920018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*